SinoMab BioScience Limited 3681.HK Stock
SinoMab BioScience Limited Price Chart
SinoMab BioScience Limited 3681.HK Financial and Trading Overview
SinoMab BioScience Limited stock price | 1.84 HKD |
Previous Close | 1.83 HKD |
Open | 1.85 HKD |
Bid | 1.8 HKD x N/A |
Ask | 1.85 HKD x N/A |
Day's Range | 1.83 - 1.88 HKD |
52 Week Range | 1.03 - 1.95 HKD |
Volume | 78.9K HKD |
Avg. Volume | 208.81K HKD |
Market Cap | 2.02B HKD |
Beta (5Y Monthly) | 0.723 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.26 HKD |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
3681.HK Valuation Measures
Enterprise Value | 2.13B HKD |
Trailing P/E | N/A |
Forward P/E | N/A |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 459.87158 |
Price/Book (mrq) | 6.468531 |
Enterprise Value/Revenue | 484.491 |
Enterprise Value/EBITDA | -10.112 |
Trading Information
SinoMab BioScience Limited Stock Price History
Beta (5Y Monthly) | 0.723 |
52-Week Change | N/A |
S&P500 52-Week Change | N/A |
52 Week High | 1.95 HKD |
52 Week Low | 1.03 HKD |
50-Day Moving Average | 1.63 HKD |
200-Day Moving Average | 1.43 HKD |
3681.HK Share Statistics
Avg. Volume (3 month) | 208.81K HKD |
Avg. Daily Volume (10-Days) | 100.17K HKD |
Shares Outstanding | 1.09B |
Float | 298.81M |
Short Ratio | N/A |
% Held by Insiders | 42.73% |
% Held by Institutions | 19.49% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2023 |
Most Recent Quarter (mrq) | December 31, 2023 |
Next Fiscal Year End | December 31, 2024 |
Profitability
Profit Margin | 0% |
Operating Margin (ttm) | 2947.04% |
Gross Margin | 78.52% |
EBITDA Margin | 0% |
Management Effectiveness
Return on Assets (ttm) | -15.46% |
Return on Equity (ttm) | -60.38% |
Income Statement
Revenue (ttm) | 4.39M HKD |
Revenue Per Share (ttm) | 0.004 HKD |
Quarterly Revenue Growth (yoy) | N/A |
Gross Profit (ttm) | N/A |
EBITDA | -210440992 HKD |
Net Income Avi to Common (ttm) | -243111008 HKD |
Diluted EPS (ttm) | -0.26 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 237.53M HKD |
Total Cash Per Share (mrq) | 0.23 HKD |
Total Debt (mrq) | 450.81M HKD |
Total Debt/Equity (mrq) | 152.52 HKD |
Current Ratio (mrq) | 1.565 |
Book Value Per Share (mrq) | 0.286 |
Cash Flow Statement
Operating Cash Flow (ttm) | -133847000 HKD |
Levered Free Cash Flow (ttm) | -244574368 HKD |
Profile of SinoMab BioScience Limited
Country | Hong Kong |
State | N/A |
City | Tai Po |
Address | No.15 Science Park West Avenue |
ZIP | N/A |
Phone | 852 3426 9833 |
Website | https://www.sinomab.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 215 |
SinoMab BioScience Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of therapeutics for the treatment of immunological diseases primarily monoclonal antibody (mAb)-based biologics. Its flagship product is SM03, a first-in-target anti-CD22 mAb, which is in Phase III clinical trial for the treatment of rheumatoid arthritis (RA), as well as in various clinical stages for other immunological diseases, such as systemic lupus erythematosus (SLE), Sjogren's syndrome (SS), and non-Hodgkin's lymphoma (NHL). The company also focuses on developing SN1011, a Bruton's tyrosine kinase inhibitor, which is in Phase II clinical trial for the treatment of pemphigus, as well as in phase 1 clinical trial to treat multiple sclerosis, SLE, and NMOSD. Its products under the preclinical stage comprise SM17 for the treatment of asthma, atopic dermatitis, and idiopathic pulmonary fibrosis; SM06 to treat RA, SLE, NMOSD, and SS; SM09 for the treatment of NHL and RA; and TNF2 for the treatment of autoimmune diseases. It operates in Mainland China, the Cayman Islands, and Hong Kong. SinoMab BioScience Limited was incorporated in 2001 and is headquartered in Tai Po, Hong Kong.
Q&A For SinoMab BioScience Limited Stock
What is a current 3681.HK stock price?
SinoMab BioScience Limited 3681.HK stock price today per share is 1.84 HKD.
How to purchase SinoMab BioScience Limited stock?
You can buy 3681.HK shares on the HKSE exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for SinoMab BioScience Limited?
The stock symbol or ticker of SinoMab BioScience Limited is 3681.HK.
Which industry does the SinoMab BioScience Limited company belong to?
The SinoMab BioScience Limited industry is Biotechnology.
How many shares does SinoMab BioScience Limited have in circulation?
The max supply of SinoMab BioScience Limited shares is 1.09B.
What is SinoMab BioScience Limited Price to Earnings Ratio (PE Ratio)?
SinoMab BioScience Limited PE Ratio is now.
What was SinoMab BioScience Limited earnings per share over the trailing 12 months (TTM)?
SinoMab BioScience Limited EPS is -0.26 HKD over the trailing 12 months.
Which sector does the SinoMab BioScience Limited company belong to?
The SinoMab BioScience Limited sector is Healthcare.